Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:14 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001048477-26-000016
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Other long-term liabilities | 6,667 | 5,537 |
| Net cash provided by operating activities | 388,760 | 359,665 |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Purchases of property, plant and equipment | (49,739) | (33,869) |
| Maturities and sales of investments | 767,277 | 195,738 |
| Purchases of investments | (25,792) | (202,433) |
| Purchase of intangible assets | (5,433) | (266) |
| Acquisition of Amicus, net of cash acquired | (5,067,630) | — |
Item 1. Financial Statements
FAQ
- What is BioMarin Pharmaceuticals's capex?
- BioMarin Pharmaceuticals (BMRN) reported capex of $28.82M in Q2 2026.
- How has BioMarin Pharmaceuticals's capex changed year-over-year?
- BioMarin Pharmaceuticals's capex increased by 68.5% year-over-year, from $17.1M to $28.82M.
- What is the long-term trend for BioMarin Pharmaceuticals's capex?
- Over 4 years (2021 to 2025), BioMarin Pharmaceuticals's capex has grown at a 1.9% compound annual growth rate (CAGR), from $95.58M to $103.04M.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about BioMarin Pharmaceuticals's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude